AtriCure Reports Strong Financial Results for 2024
AtriCure, Inc. (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation (Afib) and related conditions, recently issued its preliminary financial results for the fourth quarter and the full year of 2024. In addition, they provided exciting financial guidance for 2025, signaling strong growth and steady innovation in their product line.
Preliminary Revenue Results
The company anticipates its unaudited revenue for the fourth quarter of 2024 to reach around $124.3 million. This marks an impressive growth rate of approximately 17%, both in reported terms and on a constant currency basis compared to the same period in 2023. Analyzing the revenue further, U.S. sales are expected to be about $101.6 million, showcasing a growth of roughly 14%. International revenue is also projected to increase by approximately 28% to around $22.7 million, driven by robust performances across various product categories.
Key Growth Drivers
The remarkable fourth quarter performance can be attributed to significant growth in AtriCure's cryoSPHERE devices designed for pain management, alongside the successful adoption of AtriClip devices in open chest procedures and the advanced EnCompass clamp. These innovative products are testament to AtriCure's commitment to enhancing surgical solutions for patients globally.
Overall Annual Financial Performance
When looking at the entire year of 2024, AtriCure estimates total revenue to be approximately $465.3 million, which again reflects a growth rate of about 17% compared to the previous year. Notably, management projects a positive adjusted EBITDA ranging from $26 million to $29 million, along with an expected adjusted loss per share between $0.74 and $0.80. It is worth mentioning that adjusted EBITDA and adjusted loss figures fall under non-GAAP measures, and AtriCure plans to reconcile these to their GAAP measures in their upcoming audited results.
CEO’s Insights
Michael Carrel, AtriCure's President and Chief Executive Officer, expressed enthusiasm about the company’s progress. “2024 was another year of remarkable growth and innovation for AtriCure. We introduced several new products, expanded our franchises, and delivered best-in-class solutions for providers and patients around the world,” he stated. Carrel emphasized the business's expected momentum to continue into 2025, despite facing certain pressures within their U.S. Hybrid franchise. He clarified that their main focuses for the coming year will be growth, innovation, market expansion, and improving profitability.
2025 Financial Guidance and Projections
Looking ahead, management has provided optimistic guidance for 2025. Expected revenue is forecasted to be between $517 million to $527 million. AtriCure anticipates a positive adjusted EBITDA ranging from $40 million to $44 million, indicating solid operational efficiency and profitability. Additionally, modest cash flow generation is expected throughout the full year.
Upcoming Analyst & Investor Day
AtriCure is set to host an Analyst & Investor Day at its headquarters on March 26, 2025. The event will provide insights into their leading portfolio of products and their innovative pipeline aimed at market expansion. Michael Carrel looks forward to sharing perspectives from key opinion leaders and discussing long-term financial goals that will drive growth and profitability.
About AtriCure
AtriCure, Inc. is known for its innovative technologies tailored for treating Afib and related conditions, affecting over 59 million individuals worldwide. Their solutions are utilized by electrophysiologists, cardiothoracic, and thoracic surgeons globally. The company’s Isolator Synergy Ablation System was notably the first medical device to gain FDA approval for treating persistent Afib. Additionally, AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are recognized as the leading LAA management devices across global markets. Their Hybrid AF Therapy offers a minimally invasive approach for long-standing persistent Afib patients, while cryoSPHERE probes serve to alleviate pain during cardiac and thoracic procedures.
Frequently Asked Questions
What were AtriCure's revenue expectations for Q4 2024?
AtriCure anticipates Q4 2024 revenue to be about $124.3 million, indicating a 17% growth.
What drove AtriCure's revenue growth in 2024?
Key drivers include the success of their cryoSPHERE devices for pain management and the growing use of AtriClip devices in surgical procedures.
What is AtriCure's adjusted EBITDA outlook for 2025?
The company projects a positive adjusted EBITDA ranging from $40 million to $44 million for 2025.
When is AtriCure's Analyst & Investor Day?
The Analyst & Investor Day is scheduled for March 26, 2025, at AtriCure's headquarters.
What innovative products does AtriCure offer?
AtriCure offers a range of products for Afib treatment, including the Isolator Synergy Ablation System and AtriClip devices.
